The frequency of antiheparin−platelet factor 4 antibodies by means of antigenic and functional assays (14 C-serotonin release assay and citrated plasma platelet aggregation) was determined in 115 Turkish patients undergoing cardiac surgery. Blood samples were taken immediately before surgery and on days 5 and 10 ± 2. Platelet counts were recorded and thrombotic events were determined by clinical methods. Antibody generation measured by enzyme-linked immunosorbent assay before surgery (n = 44) and on days 5 (n = 44) and 10 (n = 115) was 15.9%, 34.1%, and 65.2%, respectively. Positive samples from functional assays were 4.4% on day 0 and 7.0% on day 10. All positive samples had been negative on day 0. A high frequency of antiheparin−platelet factor 4 antibody generation and a low frequency of clinical heparin-induced thrombocytopenia were determined in these patients. These results obtained for Turkish patients are similar to those of other studies of heparin-induced thrombocytopenia.
Fabris F., Ahmad S., Cella G., Jeske WP, Walenga JM, Fareed J.Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review. Arch Pathol Lab Med.2000;124:1657-1666.
4.
Greinacher A. , Warkentin TERecognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thromb Res.2006;118:165-176.
Walenga JM, Jeske WP, Prechel MM, Bakhos M.Newer insights on the mechanism of heparin-induced thrombocytopenia. Sem Thromb Hemost. 2004;80(suppl 1):57-67.
7.
Newman PM, Chong BHHeparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
8.
Chong BH, Burgess J., Ismail F.The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost.1993;69:344-350.
9.
Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M.Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost.1999;25(suppl 1): S43-S49.
10.
Demir M., Ahmad S., Walenga JM, Jareed J.Laboratory diagnosis of heparin-induced thrombocytopenia. Turk J Haematol.2000;17(3 suppl):181-190.
11.
Jeske WP, Walenga JM, Hoppensteadt D., Fareed J.Validity of the laboratory methods for the diagnosis of HIT. Comparative studies on C-14-serotonin release, anti-heparin/ platelet factor 4 antibodies, platelet aggregometry, and flow cytometric methods. Blood.1996;88(10 suppl):1256A
12.
Warkentin TEHeparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf.1997;17:325-341.
13.
Girolami B. , Prandoni P., Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-2959.
14.
Prandoni P. , Siragusa S., Girolami B., Fabris F.; BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106:3049-3054.
15.
Trossaert M. , Gaillard A., Commin PL, Amiral J., Vissac AM, Fressinaud E.High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol.1998;101:653-655.
16.
Bauer TL, Arepally G., Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation . 1997;95:1242-1246.
17.
Amiral J., Bridey, Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost.1992; 68:95-96.
18.
Amiral J., Vissac AMGeneration and pathogenicity of anti-platelet factor 4 antibodies: diagnostic implications. Clin Appl Thromb Hemost.1999 ;5(suppl 1):S28-S31.
19.
Sheridan D. , Carter C., Kelton JGA diagnostic test for heparin-induced thrombocytopenia . Blood. 1986;67:27-30.
20.
Mattiolli AV , Bonetti L., Sternieri S., Mattioli G.Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1-year follow-up. Ital Heart J.2000;1:39-44.
21.
Cella G., Vittadello O., Galluci V., Girolami A.The release of beta thromboglobulin and platelet factor 4 during extra-corporeal circulation for open heart surgery. Eur J Clin Invest.1981;11:165-169.
22.
Ahmad S., Iqbal O., Tobu M., Demir M.Immunobiology and pathophysiology of heparin-induced thrombocytopenia/ thrombosis syndrome-an update. Turk J Haematol.2002; 19:127-131.
23.
Mattioli AVPrevalence of anti-PF4/heparin antibodies and HIT syndrome in cardiovascular medicine. Sem Thromb Hemost . 2004;30:291-295.
24.
Konkle BA, Bauer TL, Arepally G., et al. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg.2001;71: 1920-1924.
25.
Zwicker JI, Uhl L., Huang WY, Shaz BH, Bauer KAThrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost.2004;2:2133-2137.
26.
Untch B., Ahmad S., Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res.2002;105:117-123.
27.
Warkentin TE , Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JGLaboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med.2005;146:341-346.
